Median: initial agreement with a leading oncology company

(CercleFinance.com) - Median Technologies announced today that it has signed an initial agreement with 'a top 10 global pharmaceutical company in oncology'.


The aim of the agreement is to discover imaging biomarkers by using artificial intelligence to mine clinical data from a drug candidate developed by the laboratory.

This agreement could lead to a broader collaboration between the pharmaceutical company and Median.

Copyright (c) 2024 CercleFinance.com. All rights reserved.